Form 4: Apogee CMO Sells Shares After Option Exercise

Apogee Therapeutics' Chief Medical Officer, Carl Dambkowski, exercised stock options and subsequently sold a portion of his common stock holdings under a pre-arranged trading plan.

Summary

• Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics, Inc. (APGE), reported transactions on March 4, 2026.
• Dambkowski acquired 4,125 shares of common stock by exercising stock options at a price of $22.86 per share.
• Concurrently, Dambkowski sold a total of 5,500 shares of common stock in multiple transactions.
• The sales included 3,225 shares at a weighted average price of $70.33, 2,075 shares at a weighted average price of $71.98, and 200 shares at a weighted average price of $73.26.
• All sales were executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025.
• Following these transactions, Dambkowski directly beneficially owns 209,773 shares of common stock.
• He also holds stock options representing the right to purchase 131,290 shares, with 175,345 shares vesting in equal monthly installments through December 18, 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While it involves insider selling, the transactions were pre-planned under a Rule 10b5-1 plan, mitigating concerns that the sales are based on new negative information. The exercise of options at a much lower price also indicates a personal financial planning move.

Positives

• The Chief Medical Officer exercised stock options at a significantly lower price ($22.86) compared to the market prices at which shares were sold (ranging from $70.30 to $73.31), indicating a profitable transaction for the insider.
• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which suggests a systematic approach to managing equity holdings rather than a reaction to immediate company news.

Negatives

• The insider's direct beneficial ownership of common stock decreased by a net of 1,375 shares (5,500 shares sold minus 4,125 shares acquired via option exercise), representing a reduction in direct equity exposure.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction, focusing solely on insider trading activity.

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales, are closely monitored by the market as they can sometimes signal management's perception of the company's future prospects. However, sales executed under a Rule 10b5-1 plan are generally viewed with less concern, as they are pre-scheduled and not typically indicative of new, material non-public information.

Stakeholder Impact

• Shareholders may interpret the net reduction in the Chief Medical Officer's direct common stock holdings as a slight negative, although the pre-planned nature of the sales under Rule 10b5-1 typically lessens this concern.
• The transactions demonstrate the executive's ability to monetize vested equity, which is a standard component of executive compensation.

Next Steps

• The remaining 131,290 shares underlying stock options will continue to vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer.

Key Dates

Recommendation

The insider selling, while a reduction in direct ownership, was conducted under a pre-established Rule 10b5-1 trading plan. This suggests the sales are part of a personal financial strategy rather than a reaction to new, adverse company developments. Therefore, it does not provide a strong signal for either buying or selling the stock, warranting a 'hold' recommendation based solely on this filing.

Keywords

Apogee Therapeutics, APGE, Insider Trading, Form 4, Stock Options, Rule 10b5-1, Chief Medical Officer, Equity Sales